Shire

Shire Accepts Improved $62B Bid From Takeda
Strategy

Shire Accepts Improved $62B Bid From Takeda

The deal is the largest-ever by a Japanese company and gives Takeda a lucrative portfolio of rare disease drugs.
By Matthew Heller | May 8, 2018
Read More
Ireland’s Shire Buys Baxalta for $32 Billion
Strategy

Ireland’s Shire Buys Baxalta for $32 Billion

The drug maker says the deal will further its goal of "building the leading biotechnology company focused on rare diseases."
By Katie Kuehner-Hebert | January 11, 2016
Read More
Shire to Buy Rival Drug Maker Dyax for $5.9B
Strategy

Shire to Buy Rival Drug Maker Dyax for $5.9B

The deal gives the acquisitive Irish company access to an experimental drug that competes with its own treatment for a rare disease.
By Matthew Heller | November 2, 2015
Read More
Another Tax Inversion Deal in the Works
Tax

Another Tax Inversion Deal in the Works

The hue and cry over tax inversions is not stopping companies from proceeding with more mergers that take advantage of the tactic.
By Iris Dorbian | July 28, 2014
Read More
Treasury Stance Regardless, Another Tax-Inversion Deal Pops Up
Tax

Treasury Stance Regardless, Another Tax-Inversion Deal Pops Up

AbbVie's plans to pay less taxes by relocating to Britain after buying Shire touches a raw nerve in Washington.
By Iris Dorbian | July 19, 2014
Read More